SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its highly dedicated community's relentless focus on building a real-world, permissionless brand, highlighted by ongoing product launches such as Kendu Spice and significant IRL initiatives. This unwavering commitment and 'Kendu Sendu' mindset are driving widespread bullish sentiment and active conversation across the crypto space.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is experiencing surging momentum driven by presentations at a key healthcare conference, where it is showcasing impressive pancreatic cancer data and a recent FDA submission for skin cancer. The community is buzzing with anticipation for an imminent regulatory approval in Japan and expected inclusion in a major biotech ETF, along with broader speculation about M&A activity in the red-hot precision oncology space for its innovative alpha radiation therapy. This confluence of catalysts is fueling high trading volume and a belief that the stock is poised for significant institutional attention.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics is trending after reporting positive clinical data, including the sustained complete resolution of a lung metastasis in a metastatic breast cancer patient, which initially fueled significant pre-market enthusiasm. However, this positive sentiment quickly reversed following the announcement of a large public offering with warrants, leading to a substantial share price decline. The community is vocal about this being a recurring pattern of management issuing heavy dilution after positive news, raising concerns about shareholder value.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is generating significant buzz following a rumored collaboration with POL and its integration with ACH, which the community views as a meaningful expansion of its utility. Investors are actively watching for Dash, an "OG privacy coin," to emulate the strong upward movement seen in Zcash, amidst a broader resurgence of interest in privacy tokens. This has ignited discussions around its technical chart patterns and perceived undervaluation.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is a major talking point as market participants await key economic data, including PPI, and a highly anticipated Supreme Court ruling on tariffs that could significantly impact trade policy. The community remains divided on the immediate market direction, with many weighing global geopolitical tensions and the notable strength in safe-haven assets against broader equity sentiment. This confluence of events is shaping active discussions around potential market shifts and Federal Reserve rate expectations.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as investors grapple with immediate catalysts including a highly anticipated Supreme Court ruling on US tariffs and impending PPI data, alongside escalating geopolitical tensions. While many celebrate resilient "V-shaped" recoveries driven by a strong "buy the dip" mentality, a significant portion of the community expresses frustration over perceived "algo manipulation" and questions the sustainability of current market levels for this tech-heavy index.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is actively discussed amid conflicting narratives, fueled by the viral success of new games on its platform and significant efforts to implement mandatory age verification for chat. This comes as the company faces intensified scrutiny, including multiple state lawsuits over child safety and recent analyst downgrades, sharply dividing community sentiment between growth prospects and platform risks.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Sprott Physical Silver Trust (PSLV) is trending as the community highlights a severe physical silver shortage, driven by escalating industrial demand from sectors like AI and EVs, alongside reports of constrained global supply and efforts to suppress price. Investors are actively discussing PSLV's superior physical backing compared to other silver ETFs, with many anticipating a significant market re-pricing as historical manipulation attempts face mounting pressure from fundamental supply-demand imbalances and silver's status as a critical mineral.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet (STRK) is drawing attention for its surging ecosystem growth, marked by increasing app revenue, user activity, and Total Value Locked. The community is actively discussing its unique position as a quantum-resistant Layer 2, leveraging advanced ZK-STARK technology to offer Bitcoin staking and a seamless user experience through native Account Abstraction, setting it apart from other scaling solutions.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending following the significant news of Duchenne muscular dystrophy being added to the U.S. Recommended Uniform Screening Panel, which the community views as a pivotal step for earlier diagnosis and potential treatment with Elevidys. This development, coupled with anticipation for upcoming data from its robust siRNA pipeline, is fueling active discussions about the stock's valuation, perceived short interest, and its long-term growth trajectory in the rare disease gene therapy space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CCAP Crescent Capital BDC price target lowered to $17 from $20 at BofA 
 
BofA lowered the firm&#39;s price target on Crescent Capital BDC to $17 from $20 and keeps a Buy rating on the shares. The Q1 results for the business development companies were &quot;somewhat disappointing,&quot; with profitability weaker than expected as lower rates and spreads, tariff-related macro uncertainty, and normalizing credit weighted on reports, the analyst tells investors in a research note. However, there was only as small uptick in non-accruals to 2.9%, which remain well below the industry longer-term average, adds BofA. It remains positive on the sector.

Alexander Stewart

StockTwits Web

Crescent Capital BDC Inc

 Crescent Capital BDC price target lowered to $17 from $20 at BofA 
 
BofA lowered the firm's price target on Crescent Capital BDC to $17 from $20 and keeps a Buy rating on the shares. The Q1 results for the business development companies were "somewhat disappointing," with profitability weaker than expected as lower rates and spreads, tariff-related macro uncertainty, and normalizing credit weighted on reports, the analyst tells investors in a research note. However, there was only as small uptick in non-accruals to 2.9%, which remain well below the industry longer-term average, adds BofA. It remains positive on the sector.